CDE: A Drug Enlisted in the 'SPARK Program' Pilot

1 week ago / Read about 0 minute

Author：小编

On May 29, 2025, the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) rolled out the Supportive Program for Anticancer Research in Kids (abbreviated as the SPARK Program). This pilot project is specifically designed to spur the development of pediatric antitumor medications. Recently, KC1036 tablets, put forward by Beijing Kangchen Pharmaceutical Co., Ltd., have made it onto the list of this program. The intended pediatric use for this drug is the treatment of Ewing's sarcoma. Kangchen Pharmaceutical is set to engage in proactive communication with the CDE. The aim is to drive forward the clinical development process and ultimately secure market approval for KC1036.

Previous page：SZSE Seeks Public Input on Updated Sustainability ...

Next page：CSRC Invites Public Input: Suggests Reasonable Cut...

Return to List

Hot Reading

1 day ago

Elon Musk's Grok AI Spread Ludicrous Misinformation After Charlie Kirk's Shooting, Saying Kirk Survived and Video Was Fake

1 day ago

FTC launches inquiry into AI chatbot companions from Meta, OpenAI, and others

2 day ago

OpenAI Execs Are Extremely Upset

1 day ago

Financial Experts Concerned That Driving Users Into Psychosis Will Be Bad for AI Investments